Critical Contrast: Aardvark Therapeutics (AARD) and The Competition

Aardvark Therapeutics (NASDAQ:AARD) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare Aardvark Therapeutics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, valuation, risk, institutional ownership and profitability.

Valuation and Earnings

This table compares Aardvark Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aardvark Therapeutics	N/A	-$20.59 million	-6.44
Aardvark Therapeutics Competitors	$884.18 million	-$43.85 million	10.10

Aardvark Therapeutics’ peers have higher revenue, but lower earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Aardvark Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	1	0	10	1	2.92
Aardvark Therapeutics Competitors	6642	12472	38217	1215	2.58

Aardvark Therapeutics currently has a consensus target price of $32.70, indicating a potential upside of 139.56%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 52.54%. Given Aardvark Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than its peers.

Institutional and Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 13.5% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aardvark Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-54.90%	-37.86%
Aardvark Therapeutics Competitors	-906.16%	-572.54%	-29.84%

Summary

Aardvark Therapeutics beats its peers on 7 of the 12 factors compared.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.